Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.31 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9921568 | 0.90 | MMP1 (0.31) | — | |
| SCHEMBL9921579 | 0.88 | CYP2C9 (0.35) | CNR2 | |
| SCHEMBL9905364 | 0.80 | MAPT (0.35) | CNR2MAOARIPK1ALDH1A1HPGD | |
| SCHEMBL9905183 | 0.79 | CNR2 (0.34) | CNR2MAOARIPK1PREPALDH1A1 | |
| SCHEMBL9905158 | 0.79 | CYP2C9 (0.34) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL14214195 | 0.79 | PRSS1 (0.35) | CNR2MAOARIPK1ALDH1A1HPGD | |
| SCHEMBL14214196 | 0.77 | CNR2 (0.35) | CNR2MAOAPREPALDH1A1MEN1 | |
| SCHEMBL64360 | 0.77 | CYP2C9 (0.40) | ALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL9905386 | 0.77 | CYP2C9 (0.35) | CNR2ALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL9905201 | 0.76 | CYP2C9 (0.35) | CNR2RIPK1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846659-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846659-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| EP-2649074-A1 | HIV INTEGRASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2013-10-16 | — | — | EP | disclosed |
| US-20120309745-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-06 | — | — | US | disclosed |
| US-20120309745-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-06 | — | — | US | disclosed |
| WO-2012078844-A1 | HIV INTEGRASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309745-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | CNR2 4810/4885MAOA 1379/4885RIPK1 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.